Fundraising FoxCambridge Innovation Capital — 2023 Investments
5 investments dated 2023 · listed companies and verified rows first · show all
Secondmind provides AI-powered software to help automotive engineers accelerate vehicle design and development.
AI & Machine LearningDeep TechSaaSCambridge, GB
Carl Edward Rasmussen(Chief Science Officer)inGary Brotman(Chief Executive Officer & Founder)in
Co-investorsAmadeus Capital PartnersAtlantic Bridge VenturesPassion CapitalReefknot InvestmentsSingapore Innovate Pte. Ltd.
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.
BiotechDigital HealthHealthtechMedical DevicesMunich, DE
Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in
Co-investorsBioGeneration VenturesGimvHadean VenturesSeroba Life SciencesBGVForbion+2 more
Seldon provides a Kubernetes-native MLOps and LLMOps platform for deploying, scaling, and governing machine learning and AI models in production across any cloud or on-premise environment.
AI & Machine LearningCloud ComputingDeveloper ToolsLondon, GB
Co-investorsAlbionVCAmadeus Capital PartnersBright Pixel CapitalGlobal BrainTechstarsThundermark Capital+1 more
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, GB
Co-investorsF-Prime CapitalSanofi VenturesSofinnova PartnersBusiness Growth FundDigitalis VenturesUniversity of Cambridge Enterprise
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Mosaic Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.